ISPOR - Secukinumab Vs. Adalimumab for the Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis at 48 Weeks from an Argentinian Perspective

Full Text

Secukinumab Vs. Adalimumab for the Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis at 48 Weeks from an Argentinian Perspective

Abstract

Authors

M Barbeau PM Bianculli E Nikoglou P Gunda SM Jugl A MacPherson

Back to Volume 20, Issue 9

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now